JP2007515426A - 緑内障の処置のための短い形態のｃ−Ｍａｆ転写因子アンタゴニストとしてのｃｄｋ２アンタゴニスト - Google Patents
緑内障の処置のための短い形態のｃ−Ｍａｆ転写因子アンタゴニストとしてのｃｄｋ２アンタゴニスト Download PDFInfo
- Publication number
- JP2007515426A JP2007515426A JP2006545577A JP2006545577A JP2007515426A JP 2007515426 A JP2007515426 A JP 2007515426A JP 2006545577 A JP2006545577 A JP 2006545577A JP 2006545577 A JP2006545577 A JP 2006545577A JP 2007515426 A JP2007515426 A JP 2007515426A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- glaucoma
- maf
- pervalanol
- transcription factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010089507 Proto-Oncogene Proteins c-maf Proteins 0.000 title claims abstract description 90
- 102000007987 Proto-Oncogene Proteins c-maf Human genes 0.000 title claims abstract description 79
- 239000005557 antagonist Substances 0.000 title claims abstract description 54
- 238000011282 treatment Methods 0.000 title claims description 21
- 101150073031 cdk2 gene Proteins 0.000 title claims description 16
- 208000010412 Glaucoma Diseases 0.000 title abstract description 38
- 230000014509 gene expression Effects 0.000 claims abstract description 37
- 206010030348 Open-Angle Glaucoma Diseases 0.000 claims abstract description 25
- 201000006366 primary open angle glaucoma Diseases 0.000 claims abstract description 25
- 201000005428 steroid-induced glaucoma Diseases 0.000 claims abstract description 23
- 239000000203 mixture Substances 0.000 claims description 43
- 238000000034 method Methods 0.000 claims description 28
- 239000003814 drug Substances 0.000 claims description 11
- 238000002347 injection Methods 0.000 claims description 11
- 239000007924 injection Substances 0.000 claims description 11
- 230000002401 inhibitory effect Effects 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- 208000024891 symptom Diseases 0.000 claims description 9
- CRDNMYFJWFXOCH-YPKPFQOOSA-N (3z)-3-(3-oxo-1h-indol-2-ylidene)-1h-indol-2-one Chemical compound N/1C2=CC=CC=C2C(=O)C\1=C1/C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-YPKPFQOOSA-N 0.000 claims description 8
- 102000003903 Cyclin-dependent kinases Human genes 0.000 claims description 8
- 108090000266 Cyclin-dependent kinases Proteins 0.000 claims description 8
- 238000013518 transcription Methods 0.000 claims description 8
- 230000035897 transcription Effects 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 5
- XOXOGXAIDWPAOH-OAHLLOKOSA-N (2r)-2-[[6-[(4-methoxyphenyl)methylamino]-9-propan-2-ylpurin-2-yl]amino]butan-1-ol Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)CC)=NC=1NCC1=CC=C(OC)C=C1 XOXOGXAIDWPAOH-OAHLLOKOSA-N 0.000 claims description 4
- RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical compound NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 claims description 4
- CRDNMYFJWFXOCH-BUHFOSPRSA-N Couroupitine B Natural products N\1C2=CC=CC=C2C(=O)C/1=C1/C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-BUHFOSPRSA-N 0.000 claims description 4
- PCKPVGOLPKLUHR-UHFFFAOYSA-N OH-Indolxyl Natural products C1=CC=C2C(O)=CNC2=C1 PCKPVGOLPKLUHR-UHFFFAOYSA-N 0.000 claims description 4
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 claims description 4
- 238000002513 implantation Methods 0.000 claims description 4
- XSTBCICLDQSQIQ-UHFFFAOYSA-N indeno[2,1-c]pyrazole Chemical compound C1=CC=C2C3=CN=NC3=CC2=C1 XSTBCICLDQSQIQ-UHFFFAOYSA-N 0.000 claims description 4
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical compound C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 claims description 4
- CRDNMYFJWFXOCH-UHFFFAOYSA-N isoindigotin Natural products N1C2=CC=CC=C2C(=O)C1=C1C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-UHFFFAOYSA-N 0.000 claims description 4
- 150000003212 purines Chemical class 0.000 claims description 4
- BWESROVQGZSBRX-UHFFFAOYSA-N pyrido[3,2-d]pyrimidine Chemical compound C1=NC=NC2=CC=CN=C21 BWESROVQGZSBRX-UHFFFAOYSA-N 0.000 claims description 4
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 claims description 4
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 claims description 4
- 230000000699 topical effect Effects 0.000 claims description 3
- 108091007914 CDKs Proteins 0.000 claims description 2
- 238000011200 topical administration Methods 0.000 claims 4
- BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 claims 3
- 229950010817 alvocidib Drugs 0.000 claims 3
- 229950003476 aminothiazole Drugs 0.000 claims 3
- QPCBNXNDVYOBIP-WHFBIAKZSA-N hymenialdisine Chemical compound NC1=NC(=O)C([C@@H]2[C@@H]3C=C(Br)N=C3C(=O)NCC2)=N1 QPCBNXNDVYOBIP-WHFBIAKZSA-N 0.000 claims 3
- ATBAETXFFCOZOY-UHFFFAOYSA-N hymenialdisine Natural products N1C(N)=NC(=O)C1=C1C(C=C(Br)N2)=C2C(=O)NCC1 ATBAETXFFCOZOY-UHFFFAOYSA-N 0.000 claims 3
- AHLKSOXEVRYIRD-UHFFFAOYSA-N n-phenylquinazolin-2-amine Chemical compound N=1C=C2C=CC=CC2=NC=1NC1=CC=CC=C1 AHLKSOXEVRYIRD-UHFFFAOYSA-N 0.000 claims 3
- -1 paulon Chemical compound 0.000 claims 3
- BTIHMVBBUGXLCJ-OAHLLOKOSA-N seliciclib Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)CC)=NC=1NCC1=CC=CC=C1 BTIHMVBBUGXLCJ-OAHLLOKOSA-N 0.000 claims 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 210000001585 trabecular meshwork Anatomy 0.000 abstract description 31
- 230000000694 effects Effects 0.000 abstract description 17
- 230000001105 regulatory effect Effects 0.000 abstract description 14
- 239000003112 inhibitor Substances 0.000 abstract description 11
- 230000008506 pathogenesis Effects 0.000 abstract description 7
- 102000011117 Transforming Growth Factor beta2 Human genes 0.000 abstract description 4
- 101800000304 Transforming growth factor beta-2 Proteins 0.000 abstract description 4
- 229940072041 transforming growth factor beta 2 Drugs 0.000 abstract description 4
- 230000008485 antagonism Effects 0.000 abstract description 3
- 230000001364 causal effect Effects 0.000 abstract description 3
- 239000012636 effector Substances 0.000 abstract description 3
- 150000003431 steroids Chemical class 0.000 abstract description 3
- 102000015792 Cyclin-Dependent Kinase 2 Human genes 0.000 abstract description 2
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 28
- 108090000623 proteins and genes Proteins 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 12
- 238000011529 RT qPCR Methods 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 230000004410 intraocular pressure Effects 0.000 description 9
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 7
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 6
- 229960003957 dexamethasone Drugs 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000006378 damage Effects 0.000 description 5
- 210000003733 optic disk Anatomy 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000001384 anti-glaucoma Effects 0.000 description 3
- 210000001742 aqueous humor Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 210000004087 cornea Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 238000002493 microarray Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 229940054534 ophthalmic solution Drugs 0.000 description 3
- 239000002997 ophthalmic solution Substances 0.000 description 3
- 210000001328 optic nerve Anatomy 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 210000003705 ribosome Anatomy 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108020004463 18S ribosomal RNA Proteins 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- 206010015946 Eye irritation Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 210000003050 axon Anatomy 0.000 description 2
- 239000002876 beta blocker Substances 0.000 description 2
- 229940097320 beta blocking agent Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 231100000013 eye irritation Toxicity 0.000 description 2
- 239000003885 eye ointment Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 210000003994 retinal ganglion cell Anatomy 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 240000005020 Acaciella glauca Species 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 229940121805 Cyclin A inhibitor Drugs 0.000 description 1
- 102000000578 Cyclin-Dependent Kinase Inhibitor p21 Human genes 0.000 description 1
- 108010016788 Cyclin-Dependent Kinase Inhibitor p21 Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102000007307 Maf Transcription Factors Human genes 0.000 description 1
- 108010033714 Maf Transcription Factors Proteins 0.000 description 1
- 102000039538 Maf family Human genes 0.000 description 1
- 108091067370 Maf family Proteins 0.000 description 1
- 206010027417 Metabolic acidosis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000009795 Microphthalmos Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 108091005461 Nucleic proteins Chemical group 0.000 description 1
- 102000007354 PAX6 Transcription Factor Human genes 0.000 description 1
- 101150081664 PAX6 gene Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- RAMROQQYRRQPDL-HNNXBMFYSA-N aminopurvalanol Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)C(C)C)=NC=1NC1=CC(N)=CC(Cl)=C1 RAMROQQYRRQPDL-HNNXBMFYSA-N 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000011278 co-treatment Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 231100000040 eye damage Toxicity 0.000 description 1
- 230000004373 eye development Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 201000010478 microphthalmia Diseases 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000003547 miosis Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- GTVPOLSIJWJJNY-UHFFFAOYSA-N olomoucine Chemical compound N1=C(NCCO)N=C2N(C)C=NC2=C1NCC1=CC=CC=C1 GTVPOLSIJWJJNY-UHFFFAOYSA-N 0.000 description 1
- 229940100655 ophthalmic gel Drugs 0.000 description 1
- 229940069265 ophthalmic ointment Drugs 0.000 description 1
- 229940100654 ophthalmic suspension Drugs 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- ZKDXRFMOHZVXSG-HNNXBMFYSA-N purvalanol B Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)C(C)C)=NC=1NC1=CC=C(C(O)=O)C(Cl)=C1 ZKDXRFMOHZVXSG-HNNXBMFYSA-N 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 235000003499 redwood Nutrition 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 229940064707 sympathomimetics Drugs 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229940042596 viscoat Drugs 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53180103P | 2003-12-22 | 2003-12-22 | |
| PCT/US2004/042930 WO2005063252A1 (en) | 2003-12-22 | 2004-12-21 | Cdk2 antagonists as short form c-maf transcription factor antagonists for treatment of glaucoma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007515426A true JP2007515426A (ja) | 2007-06-14 |
| JP2007515426A5 JP2007515426A5 (https=) | 2007-12-06 |
Family
ID=34738702
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006545577A Pending JP2007515426A (ja) | 2003-12-22 | 2004-12-21 | 緑内障の処置のための短い形態のｃ−Ｍａｆ転写因子アンタゴニストとしてのｃｄｋ２アンタゴニスト |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20050159432A1 (https=) |
| EP (1) | EP1696928A1 (https=) |
| JP (1) | JP2007515426A (https=) |
| KR (1) | KR20060110301A (https=) |
| CN (1) | CN1886138A (https=) |
| AR (1) | AR046728A1 (https=) |
| AU (1) | AU2004308938B2 (https=) |
| BR (1) | BRPI0418033A (https=) |
| CA (1) | CA2548035A1 (https=) |
| MX (1) | MXPA06007062A (https=) |
| RU (1) | RU2370267C2 (https=) |
| TW (1) | TW200526224A (https=) |
| UY (1) | UY28660A1 (https=) |
| WO (1) | WO2005063252A1 (https=) |
| ZA (1) | ZA200604576B (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2548146A1 (en) * | 2003-12-22 | 2005-07-14 | Alcon, Inc. | Agents for treatment of diabetic retinopathy and drusen formation in macular degeneration |
| MXPA06006980A (es) * | 2003-12-22 | 2006-12-14 | Alcon Inc | Agentes para tratamiento de retinopatia glaucomatosa y neuropatia optica. |
| US20050222127A1 (en) * | 2004-03-30 | 2005-10-06 | Alcon, Inc. | Use of Rho kinase inhibitors in the treatment of hearing loss, tinnitus and improving body balance |
| US20060115870A1 (en) * | 2004-03-30 | 2006-06-01 | Alcon, Inc. | High throughput assay for human Rho kinase activity |
| US20080096238A1 (en) * | 2004-03-30 | 2008-04-24 | Alcon, Inc. | High throughput assay for human rho kinase activity with enhanced signal-to-noise ratio |
| DK2444807T3 (da) * | 2006-11-01 | 2014-08-11 | Ventana Med Syst Inc | Mono- og dinitropyrazolhaptenkonjugater |
| WO2008079980A1 (en) * | 2006-12-22 | 2008-07-03 | Alcon Research, Ltd. | Inhibitors of protein kinase c-delta for the treatment of glaucoma |
| US7682789B2 (en) * | 2007-05-04 | 2010-03-23 | Ventana Medical Systems, Inc. | Method for quantifying biomolecules conjugated to a nanoparticle |
| EP2167963B1 (en) | 2007-05-23 | 2019-04-17 | Ventana Medical Systems, Inc. | Polymeric carriers for immunohistochemistry and in situ hybridization |
| WO2009149013A2 (en) | 2008-06-05 | 2009-12-10 | Ventana Medical Systems, Inc. | Compositions comprising nanomaterials and method for using such compositions for histochemical processes |
| USPP22463P3 (en) * | 2010-02-16 | 2012-01-17 | Menachem Bornstein | Gypsophila plant named ‘Pearl Blossom’ |
| EP3517630B1 (en) | 2010-10-06 | 2022-01-19 | Institució Catalana de Recerca i Estudis Avançats | Method for the diagnosis, prognosis and treatment of breast cancer metastasis |
| EP2650682A1 (en) | 2012-04-09 | 2013-10-16 | Fundació Privada Institut de Recerca Biomèdica | Method for the prognosis and treatment of cancer metastasis |
| EP3467124A1 (en) | 2012-06-06 | 2019-04-10 | Fundació Institut de Recerca Biomèdica IRB (Barcelona) | Method for the diagnosis, prognosis and treatment of lung cancer metastasis |
| US10119171B2 (en) | 2012-10-12 | 2018-11-06 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
| KR101872965B1 (ko) | 2012-10-12 | 2018-06-29 | 인바이오모션 에스.엘. | Ｃ―ｍａｆ를 이용하는 전립선암 전이의 진단, 예후 및 치료 방법 |
| JP6577873B2 (ja) | 2013-03-15 | 2019-09-18 | フンダシオ、インスティトゥト、デ、レセルカ、ビオメディカ（イエレベ、バルセロナ）Ｆｕｎｄａｃｉｏ Ｉｎｓｔｉｔｕｔ Ｄｅ Ｒｅｃｅｒｃａ Ｂｉｏｍｅｄｉｃａ （Ｉｒｂ Ｂａｒｃｅｌｏｎａ） | がんの転移の予後診断および処置のための方法 |
| WO2014184679A2 (en) | 2013-03-15 | 2014-11-20 | Inbiomotion S.L. | Method for the prognosis and treatment of renal cell carcinoma metastasis |
| CA2903306A1 (en) | 2013-03-15 | 2014-09-18 | Fundacio Institut De Recerca Biomedica (Irb Barcelona) | Method for the diagnosis, prognosis and treatment of metastatic cancer |
| TR201907389T4 (tr) | 2013-10-09 | 2019-06-21 | Fundacio Inst De Recerca Biomedica Irb Barcelona | Meme kanserinden kaynaklanan metastazlı kemik kanserinin prognozu ve tedavisine yönelik yöntem. |
| AU2017271385B2 (en) | 2016-05-25 | 2023-10-05 | Inbiomotion S.L. | Therapeutic treatment of breast cancer based on c-MAF status |
| MX2020005182A (es) | 2017-11-22 | 2020-08-17 | Inbiomotion Sl | Tratamiento terapeutico del cancer de mama basado en el estado del c-maf. |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997030701A2 (en) * | 1996-02-21 | 1997-08-28 | Wisconsin Alumni Research Foundation | Pharmaceutical compositions for the treatment of glaucoma |
| WO1999007705A1 (en) * | 1997-08-07 | 1999-02-18 | The Regents Of The University Of California | Purine inhibitor of protein kinases, g proteins and polymerases |
| WO2002012250A2 (en) * | 2000-08-09 | 2002-02-14 | Agouron Pharmaceuticals, Inc. | Pyrazole-thiazole compounds, pharmaceutical compositions containing them, and methods of their use for inhibiting cyclin-dependent kinases |
| WO2003027275A1 (en) * | 2001-09-27 | 2003-04-03 | Alcon, Inc. | Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma |
| US20030083346A1 (en) * | 2001-08-31 | 2003-05-01 | May Jesse A. | Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma |
| WO2003092584A2 (en) * | 2002-04-30 | 2003-11-13 | Alcon, Inc. | Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4456757A (en) * | 1981-03-20 | 1984-06-26 | Asahi Kasei Kogyo Kabushiki Kaisha | Isoquinolinesulfonyl derivatives and process for the preparation thereof |
| US4678783B1 (en) * | 1983-11-04 | 1995-04-04 | Asahi Chemical Ind | Substituted isoquinolinesulfonyl compounds |
| US4959389A (en) * | 1987-10-19 | 1990-09-25 | Speiser Peter P | Pharmaceutical preparation for the treatment of psoriatic arthritis |
| US5124154A (en) * | 1990-06-12 | 1992-06-23 | Insite Vision Incorporated | Aminosteroids for ophthalmic use |
| JP3193301B2 (ja) * | 1995-09-14 | 2001-07-30 | 麒麟麦酒株式会社 | 生理活性タンパク質ｐ１６０ |
| US5906819A (en) * | 1995-11-20 | 1999-05-25 | Kirin Beer Kabushiki Kaisha | Rho target protein Rho-kinase |
| US5681854A (en) * | 1995-11-22 | 1997-10-28 | Alcon Laboratories, Inc. | Use of aliphatic carboxylic acid derivatives in ophthalmic disorders |
| ATE289815T1 (de) * | 1995-12-21 | 2005-03-15 | Alcon Lab Inc | Verwendung von substituierten isochinolinsulfonyl-verbindungen zur herstellung eines medikaments für die behandlung von glaukom und okularer ischämie |
| ES2205166T3 (es) * | 1996-02-02 | 2004-05-01 | D. Western Therapeutics Institute | Derivados de isoquinolina y medicamento. |
| US6586425B2 (en) * | 1996-02-21 | 2003-07-01 | Wisconsin Alumni Research Foundation | Cytoskeletal active agents for glaucoma therapy |
| BR9711154A (pt) * | 1996-08-12 | 1999-08-17 | Yoshitomi Pharmaceutical | Agente farmac-utico contendo inibidor cinase rho |
| US5759787A (en) * | 1996-08-26 | 1998-06-02 | Tularik Inc. | Kinase assay |
| US6573044B1 (en) * | 1997-08-07 | 2003-06-03 | The Regents Of The University Of California | Methods of using chemical libraries to search for new kinase inhibitors |
| US6441033B1 (en) * | 1997-12-22 | 2002-08-27 | Alcon Manufacturing, Ltd. | 11β-fluoro 15β-hydroxy PGF2α analogs as FP receptor antagonists |
| US6274338B1 (en) * | 1998-02-24 | 2001-08-14 | President And Fellows Of Harvard College | Human c-Maf compositions and methods of use thereof |
| GB9806739D0 (en) * | 1998-03-28 | 1998-05-27 | Univ Newcastle Ventures Ltd | Cyclin dependent kinase inhibitors |
| US20010041174A1 (en) * | 1998-11-24 | 2001-11-15 | Najam Sharif | Use of implanted encapsulated cells expressing glutamate transporter proteins for the treatment of neurodegenerative diseases |
| BR9916327A (pt) * | 1998-12-17 | 2001-09-18 | Hoffmann La Roche | Oxindóis de 4-alquenila (e alquinila) como inibidores de cinases dependentes de ciclina, em particular, cdk2 |
| US6020383A (en) * | 1999-01-11 | 2000-02-01 | Eastman Chemicals Company | Method for reducing blood cholesterol and/or blood triglycerides |
| US6103756A (en) * | 1999-08-11 | 2000-08-15 | Vitacost Inc. | Ocular orally ingested composition for prevention and treatment of individuals |
| US6573299B1 (en) * | 1999-09-20 | 2003-06-03 | Advanced Medical Instruments | Method and compositions for treatment of the aging eye |
| WO2002002190A2 (en) * | 2000-07-05 | 2002-01-10 | Johns Hopkins School Of Medicine | Prevention and treatment of neurodegenerative diseases by glutathione and phase ii detoxification enzymes |
| GB0030727D0 (en) * | 2000-12-15 | 2001-01-31 | Lumitech Uk Ltd | Methods and kits for detecting kinase activity |
| US6756063B2 (en) * | 2001-03-29 | 2004-06-29 | Zoltan Laboratories, Llc | Methods and compositions for the treatment of human and animal cancers |
| US20030219846A1 (en) * | 2002-02-28 | 2003-11-27 | Pfizer Inc. | Assay for activity of the ActRIIB kinase |
| US7196090B2 (en) * | 2002-07-25 | 2007-03-27 | Warner-Lambert Company | Kinase inhibitors |
| CN100497302C (zh) * | 2002-09-05 | 2009-06-10 | 神经研究公司 | 二芳基脲衍生物和它们作为氯通道阻滞剂的用途 |
| US6747025B1 (en) * | 2002-11-27 | 2004-06-08 | Allergan, Inc. | Kinase inhibitors for the treatment of disease |
-
2004
- 2004-11-15 TW TW093134904A patent/TW200526224A/zh unknown
- 2004-11-26 AR ARP040104413A patent/AR046728A1/es not_active Application Discontinuation
- 2004-12-08 UY UY28660A patent/UY28660A1/es not_active Application Discontinuation
- 2004-12-21 US US11/018,283 patent/US20050159432A1/en not_active Abandoned
- 2004-12-21 CN CNA200480035441XA patent/CN1886138A/zh active Pending
- 2004-12-21 AU AU2004308938A patent/AU2004308938B2/en not_active Ceased
- 2004-12-21 WO PCT/US2004/042930 patent/WO2005063252A1/en not_active Ceased
- 2004-12-21 EP EP04815051A patent/EP1696928A1/en not_active Withdrawn
- 2004-12-21 CA CA002548035A patent/CA2548035A1/en not_active Abandoned
- 2004-12-21 JP JP2006545577A patent/JP2007515426A/ja active Pending
- 2004-12-21 KR KR1020067010098A patent/KR20060110301A/ko not_active Ceased
- 2004-12-21 RU RU2006126638/14A patent/RU2370267C2/ru not_active IP Right Cessation
- 2004-12-21 ZA ZA200604576A patent/ZA200604576B/en unknown
- 2004-12-21 BR BRPI0418033-0A patent/BRPI0418033A/pt not_active IP Right Cessation
- 2004-12-21 MX MXPA06007062A patent/MXPA06007062A/es not_active Application Discontinuation
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997030701A2 (en) * | 1996-02-21 | 1997-08-28 | Wisconsin Alumni Research Foundation | Pharmaceutical compositions for the treatment of glaucoma |
| WO1999007705A1 (en) * | 1997-08-07 | 1999-02-18 | The Regents Of The University Of California | Purine inhibitor of protein kinases, g proteins and polymerases |
| WO2002012250A2 (en) * | 2000-08-09 | 2002-02-14 | Agouron Pharmaceuticals, Inc. | Pyrazole-thiazole compounds, pharmaceutical compositions containing them, and methods of their use for inhibiting cyclin-dependent kinases |
| US20030083346A1 (en) * | 2001-08-31 | 2003-05-01 | May Jesse A. | Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma |
| WO2003027275A1 (en) * | 2001-09-27 | 2003-04-03 | Alcon, Inc. | Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma |
| WO2003092584A2 (en) * | 2002-04-30 | 2003-11-13 | Alcon, Inc. | Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004308938B2 (en) | 2011-06-23 |
| ZA200604576B (en) | 2007-11-28 |
| RU2006126638A (ru) | 2008-01-27 |
| RU2370267C2 (ru) | 2009-10-20 |
| UY28660A1 (es) | 2005-07-29 |
| EP1696928A1 (en) | 2006-09-06 |
| TW200526224A (en) | 2005-08-16 |
| CA2548035A1 (en) | 2005-07-14 |
| AR046728A1 (es) | 2005-12-21 |
| MXPA06007062A (es) | 2006-09-04 |
| AU2004308938A1 (en) | 2005-07-14 |
| KR20060110301A (ko) | 2006-10-24 |
| BRPI0418033A (pt) | 2007-04-17 |
| WO2005063252A1 (en) | 2005-07-14 |
| US20050159432A1 (en) | 2005-07-21 |
| CN1886138A (zh) | 2006-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007515426A (ja) | 緑内障の処置のための短い形態のｃ−Ｍａｆ転写因子アンタゴニストとしてのｃｄｋ２アンタゴニスト | |
| Zhou et al. | Involvement of inflammation, degradation, and apoptosis in a mouse model of glaucoma | |
| AU2008264214B2 (en) | Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (CTGF) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies | |
| CN101674824A (zh) | 使用补体因子d抑制剂治疗老年性黄斑变性 | |
| ES2424123T3 (es) | Inhibidores de MAPK p38 para uso en el tratamiento de hipertensión ocular | |
| JP2009544734A (ja) | 目の障害の予防および処置のための内皮分化遺伝子ファミリー３（ｅｄｇ−３、ｓ１ｐ３）レセプターのアンタゴニスト | |
| JP2025061389A (ja) | 細胞外マトリックス調節剤 | |
| KR20080087814A (ko) | 보체 인자 ｈ의 위험 변이체가 있는 환자에서 연령 관련황반변성의 예방 및 치료를 위한 ｃ3-전환효소 저해제 | |
| EP1925306A2 (en) | Agents which Regulate, Inhibit, or Modulate the Activity and/or Expression of Connective Tissue Growth Factor (CTGF) to Lower Intraocular Pressure | |
| Mokbel et al. | Rho-Kinase Inhibitors as a novel medication for Glaucoma Treatment–A Review of the literature | |
| WO2004047868A1 (ja) | Limキナーゼ阻害作用を有する化合物を有効成分とする緑内障治療剤 | |
| KR20080111092A (ko) | 고안압증 조절 및 녹내장의 치료를 위한 프레닐트랜스퍼라아제 억제제 | |
| JP2023547441A (ja) | 萎縮型加齢黄斑変性、地図状萎縮および緑内障関連神経変性の処置において使用するためのｎｏ－ｐｄｅ５阻害剤 | |
| HK1142832A (en) | Cdk inhibitors for lowering intraocular pressure | |
| JP2004189735A (ja) | Ｌｉｍキナーゼ阻害作用を有する化合物を有効成分とする緑内障治療剤 | |
| HK1120423A (en) | Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) to lower intraocular pressure | |
| HK1091714A (en) | Gsk-3 inhibitors and cdk inhibitors as anti-glaucoma agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20071001 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071022 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100823 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101124 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110412 |